Education
About Us
Working with TipRanks
Follow Us
Clearside Biomedical (CLSD)
NASDAQ:CLSD
Earnings Data
Report Date
May 08, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.11Last Year’s EPS
-0.17Same Quarter Last Year
Strong Buy
Based on 5 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 27, 2025
|% Change Since: -7.77%
|Next Earnings Date:May 08, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in clinical trials and regulatory approvals, particularly in the Asia-Pacific region. However, the company faces challenges in securing funding for its Phase 3 program, which is crucial for its future success. The sentiment is positive due to the strong trial results and strategic partnerships, despite the funding and enrollment challenges.Company Guidance
During the Clearside Biomedical Fourth Quarter 2024 Financial Results and Corporate Update Call, the company provided detailed guidance on its Phase 3 plans for the CLS-AX treatment for wet AMD. The pivotal Phase 3 program will consist of two non-inferiority trials, aiming to enroll treatment-naive patients, with a planned duration of enrollment of around 12 months. The design includes a personalized treatment interval (PTI) assessment at weeks 12, 16, and 20 to determine dosing regimens of every 12, 16, 20, or 24 weeks. The trials will use advanced OCT biomarkers to guide redosing, with an emphasis on reducing variability by excluding participants with significant non-disease-related visual acuity changes prior to randomization. The total cost of the trials is estimated at $55-$60 million each, with Clearside actively exploring funding options, including potential partnerships. The company also highlighted its strategic focus on suprachoroidal delivery, with ongoing collaborations and a robust pipeline, despite reporting cash and cash equivalents of approximately $20 million as of December 31, 2024.Positive Results from ODYSSEY Phase 2b Trial
Clearside's ODYSSEY Phase 2b wet AMD clinical trial showed positive results, leading to a successful end of Phase 2 meeting with the FDA. The company is aligned on a pivotal Phase 3 program for CLS-AX, setting it up for potential commercial success.
Regulatory Progress and Partnerships in Asia-Pacific
Arctic Vision achieved several regulatory milestones in the Asia-Pacific region with ARCATUS/XIPERE, including approval in Australia and Singapore and a new drug application under review in China. A commercial collaboration with Santen Pharmaceuticals was also established.
Strong Financial Position
As of December 31, 2024, the company had cash and cash equivalents totaling approximately $20 million, with resources to fund operations into the fourth quarter of 2025.
---
CLSD Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
CLSD Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 27, 2025 | $1.03 | $0.95 | -7.77% |
| Nov 12, 2024 | $1.11 | $1.08 | -2.70% |
| Aug 12, 2024 | $1.07 | $1.06 | -0.93% |
| May 09, 2024 | $1.35 | $1.25 | -7.41% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Clearside Biomedical (CLSD) report earnings?
Clearside Biomedical (CLSD) is schdueled to report earning on May 08, 2025, TBA Not Confirmed.
What is Clearside Biomedical (CLSD) earnings time?
Clearside Biomedical (CLSD) earnings time is at May 08, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CLSD EPS forecast?
CLSD EPS forecast for the fiscal quarter 2025 (Q1) is -0.11.
---